Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer ...

Catch up on all the biggest pharma news to hit the industry last month, spanning from new acquisitions, insights on the NHS ...

Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation CDK inhibitors for the treatment of breast cancer. The purchase agreement was announced at Roche’s ...

for a portfolio of CDK inhibitors for treating breast cancer. Genentech will be responsible for clinical development, manufacturing, and commercialization; Regor will manage the two ongoing Phase ...

is part of Regor Therapeutics Group, a clinical-stage biotechnology company, has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

AUSTIN, Texas--(BUSINESS WIRE)--CDK, the leading automotive retail software provider, today announced a long-term extension of its agreement with AutoCanada Inc. (TSX: ACQ), a multi-location North ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation CDK inhibitors for the treatment of breast cancer. The purchase agreement was announced at Roche’s Pharma Day.